Highlights Oramed Pharmaceuticals Inc.

Equities

ORMP

US68403P2039

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
2.395 ^USD	+0.63%		+1.91%	+3.68%

19/03	Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	CI
06/03	Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	22/23/22	MT
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	21/23/21	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.	07/23/07	CI
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture	02/23/02	MT
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally	02/23/02	CI
Oramed Pharmaceuticals Inc. Announces its Chinese Partner, Hefei Tianhui Biotechnology Co. Ltd. Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China	15/23/15	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	07/23/07	CI
Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes	12/23/12	CI
Oramed Pharmaceuticals Secures US Patent for Diabetes Combination Therapy	04/23/04	MT
Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes	04/23/04	CI
Oramed Pharmaceuticals Reports Additional Positive Mid-Stage Data for Oral Insulin Candidate	18/22/18	MT
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH	17/22/17	CI
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea	14/22/14	CI
Earnings Flash (ORMP) ORAMED PHARMACEUTICALS Reports Q3 Revenue $682,000	11/22/11	MT
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate	13/22/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oramed Pharmaceuticals Inc.

Equities

ORMP

US68403P2039

Highlights

Filters